Abstract：Objective To explore the effect of Probucol combined with Rosuvastatin on inflammatory mediators and related laboratory indicators in patients with cerebral infarction. Methods A total of 106 patients with cerebral infarction admitted to the First Affiliated Hospital of Xiamen University from December 2019 to February 2021 were selected and divided into control group (53 cases) and observation group (53 cases) according to the random number table method.The control group was treated with Rosuvastatin, and the observation group was treated with Probucol on the basis of the control group. The inflammatory mediators, serum neuron-specific enolase (NSE), central nervous system-specific protein (S100β), human chitinase protein 40 (YKL-40) and blood lipid levels were compared between the two groups.Results After treatment in the observation group, tumor necrosis factor-α (TNF-α), procalcitonin (PCT), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and matrix metalloproteinase 9 (MMP-9) level were lower than those in the control group, the levels of NSE, S100β, and YKL-40 were lower than those in the control group, and the levels of total cholesterol (TG), total cholesterol (TC), and low-density lipoprotein (LDL-C) were lower those in the control group, high-density lipoprotein (HDL-C) was higher than that in the control group, the differences were statistically significant (P<0.05); the difference between the two groups of adverse reactions was not statistically significant (P>0.05). Conclusion Probucol combined with Rosuvastatin treatment in patients with cerebral infarction can effectively reduce inflammation, reduce nerve damage, regulate blood lipid levels, and promote neurological function improvement.It is safe and reliable.
京公网安备 11010502046607号